The questions pharmaceutical digital investment rarely asks — and why it matters.
Articles and perspectives on the FC Model™, digital investment maturity, and the structural patterns that repeat across pharmaceutical and biotechnology organisations of every size and every region.
Why Pharmaceutical Digital Investment Gets Stuck at Level 1 — And What to Do About It
Four of the seven cases in the book stayed at Level 1 — Compliant. Not through incompetence. Not through poor judgment. Through a structural pattern: the approval process only ever asked for Level 1 value — can we prove this works? — when the organisation needed systems that worked at Level 2 or Level 3.
This article explains why the pattern is structural, what it costs per quarter, and the three decisions — made before scope is written — that determine whether the next investment breaks the cycle.
"Nobody in the room noticed the gap, because nobody had a shared language for asking the right question at the right moment. The FC Model™ is that language."
The FC Model™ in practice.
Six articles launching August 2026 — each one grounded in the cases from the book and the FC Model™ framework.
The Greenfield Trap: Why a Clean IT Slate Is No Guarantee of Level 2
Case 1 vs. Case 7. The same IT greenfield opportunity. One architectural decision made differently. Two completely different FC Model™ levels — and a decade of compounding difference in what the organisation could learn from its data.
Read on LinkedIn →The CFO Who Changed Everything: What Level 2 Capability Actually Requires
In Case 6, the CFO saw something most ERP project sponsors miss — the Level 2 opportunity hiding inside the technical project — and personally drove the organisation to capture it. What he saw, and how he framed it in the approval room.
Read on LinkedIn →The Data Standards Decision Nobody Makes — Until It Becomes Expensive
In Case 3, the ERP connected systems but not data. In Case 4, every site became its own data kingdom. The decision that was not made at the beginning is the decision you will be making — expensively and reactively — for years afterward.
Read on LinkedIn →The Cost Nobody Measures: What Staying at Level 1 Is Actually Costing Your Organisation
Every case in the book carries an invisible cost that does not appear in the project budget, the post-implementation review, or the annual report. In Case 5, a Lean Sigma project found almost S$120,000 in annual savings that had been accumulating silently for years. Nobody had measured it.
Read on LinkedIn →One Identifier. All Systems Connected. The Single Decision That Made Level 3 Possible
Case 7 — the only Level 3 case in the book. One architectural commitment, made before the first system was selected: every batch identifier would propagate across every system. That single decision, made with the right foresight at design stage, is what made the virtuous learning cycle possible years later.
Read on LinkedIn →When the Operator Isn't Human: The Accountability Question GMP Frameworks Weren't Designed to Answer
The bonus chapter from the book — updated with the first dedicated EU GMP Annex 22 framework for AI in pharmaceutical manufacturing, published for consultation in July 2025 and not yet finalised. A framework that acknowledges the question without yet fully answering it.
Read on LinkedIn →The pattern, one observation at a time.
Short-form posts from LinkedIn — the FC Model™ applied to the situations pharmaceutical and biotechnology organisations actually face.
"Level 1 — Compliant is not failure. It is the minimum viable state."
The problem is not that four of seven cases in the book stayed at Level 1. The problem is that none of them were designed for Level 2 — and nobody noticed the gap until after go-live, when changing it had become expensive.
Read on LinkedIn →The day after go-live, what was the first question asked of the integrated data?
In Case 5, the harmonised data platform was capable of answering Level 2 questions across all three FC Model™ dimensions the day after go-live. None of those questions were in the original business case. None were asked afterward. The data existed. The question did not.
Read on LinkedIn →Three diagnostic questions that change what gets designed for the next five years.
The FC Model™ provides one question for each level of maturity. They take minutes to answer honestly. But nobody asks them before the approval is granted — which is exactly when the answer matters most.
Read on LinkedIn →The technology never once let anyone down. What ran short was the nerve to ask for more.
Every case in the book used technology that worked. The gap was not between what the system was capable of and what was installed. The gap was between what the organisation approved and what it actually needed.
Read on LinkedIn →The most valuable moment to apply these ideas is before the next investment is approved.
The book is available freely to the industry. A first advisory conversation takes thirty minutes.